Author

L. R. Blankenship

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:virus· 2 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1

Frequent Co-Authors

K. S. Yang· 3 shared S. Xu· 3 shared W. R. Liu· 3 shared B. Sankaran· 2 shared E. C. Vatansever· 2 shared P. Li· 2 shared X. R. Ma· 2 shared Y. J. Sheng· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

K. S. Yang

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BiochemistrybioRxivJan 17, 2023

A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease

Z. Z. Geng, S. Atla, N. Shaabani…·W. R. Liu

This study systematically evaluates dipeptidyl inhibitors of SARS-CoV-2 main protease, identifying compounds with high antiviral potency and low cytotoxicity.

DOI 10.1021/acs.jmedchem.3c00221

virusexperimental assay

𝕏 PostBluesky

BiochemistrybioRxivPreprintApr 29, 2022

A Novel Y-Shaped, S-O-N-O-S-Bridged Crosslink between Three Residues C22, C44, and K61 Is a Redox Switch of the SARS-CoV-2 Main Protease

K. S. Yang, S.-T. A. Kuo, L. R. Blankenship…·W. R. Liu

The paper identifies a novel Y-shaped crosslink in SARS-CoV-2 MPro that acts as a redox switch, regulating its catalytic activity and offering new targets for antiviral drug development.

DOI 10.1101/2022.04.29.490044

virusprotein structure

𝕏 PostBluesky

BiochemistrybioRxivPreprintJul 28, 2020

A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors

W. R. Liu, K. S. Yang, X. R. Ma…·H. S. Hayatshahi

This study designs and synthesizes potent SARS-CoV-2 main protease inhibitors, with some showing IC50 values below 100 nM and high virus inhibition potency in cell assays.

DOI 10.1101/2020.07.28.223784

experimental assaydrug response / drug discovery

𝕏 PostBluesky